<DOC>
	<DOCNO>NCT02352922</DOCNO>
	<brief_summary>The investigator study way improve pain control surgery . One way decrease pain inject incision numb medicine ( local anesthetic ) operating room . There FDA approve extended-release version commonly use local anesthetic ( bupivacaine ) last 4 day instead 6 hour . The investigator study whether use extended-release medication ( Exparel ) give good pain relief laparoscopic robotic-assisted hysterectomy .</brief_summary>
	<brief_title>Randomized Trial Wound Infiltration With Extended-release Bupivacaine Before Laparoscopic Robotic Hysterectomy</brief_title>
	<detailed_description>Lidocaine bupivacaine hydrochloride ( HCl ) commonly use drug wound infiltration laparoscopic surgery post-operative pain control . There evidence wound infiltration decrease immediate post-operative pain . While bupivacaine slightly slow onset action ( 5-10 minute ) , become preferred injectable anesthetic surgical use long duration effect ( 4-8 hour versus 1-2 hour lidocaine ) . DepoFoam bupivacaine ( EXPAREL , Pacira Pharmaceuticals , Inc. , Parsippany , NJ , USA ) new extended-release formulation bupivacaine HCl approve U.S. Federal Drug Administration October 2011 . In suspension , bupivacaine encapsulate microscopic spherical lipid-based particle vary size allow dispersion drug extend period time . Analgesia prolong 96 hour . Given extend duration action , liposomal bupivacaine may better provide post-operative pain relief laparoscopic surgery . Phase three trial show well pain control first 24 hour less opioid use overall bunionectomies , hemorrhoidectomy , total knee replacement surgery compare placebo . No study , however , publish evaluate extended-release liposomal bupivacaine laparoscopic surgery , gynecologic surgery general . Currently , use liposomal bupivacaine pain relief laparoscopic hysterectomy , state , never formally evaluate . We hypothesize liposomal bupivacaine ( `` extended-release '' ) provide extended pain relief decrease need supplemental opioid use major laparoscopic surgery . We evaluate whether pre-incision infiltration extended-release bupivacaine decrease post-operative pain laparoscopic robotic-assisted hysterectomy compare bupivacaine HCl ( `` short-acting '' ) . To achieve evaluation design double-blinded randomized control trial . Patients schedule undergo laparoscopic robotic-assisted hysterectomy invited participate . Group A receive pre-incision infiltration trocar site 4 ml 0.25 % Bupivacaine HCl . Group B receive pre-incision infiltration trocar site 4 ml extended-release bupivacaine ( EXPAREL ) ( 13.3mg/ml ) . Subjects outcome assessor blind group allocation . Data collect patient hospital pain level consumption opioid pain medication . Upon discharge , pain level , functioning , quantity opioid non-steroidal anti-inflammatory ( NSAID ) pain medication collect online questionnaire . Subjects follow 2-3 week post-operative visit .</detailed_description>
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Bupivacaine</mesh_term>
	<criteria>1 . Benign indication surgery 2 . Planned multiport laparoscopic robotic assist hysterectomy 3 . Nonpregnant 4 . Able provide inform consent 5 . Owns smartphone computer internet access 6 . Willing provide contact phone number accept SMS text message 7 . Ability speak read English ( texts online survey English ) 1 . Planned additional procedure ( e.g . incontinence surgery , prolapse repair bowel surgery ) 2 . Contraindication study drug 1 . Severe Hepatic disease 2 . Severe Kidney disease 3 . Current use monoamine oxidase inhibitor 4 . Current use tricyclic antidepressant 3 . History substance alcohol abuse within past 2 year</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Laparoscopy</keyword>
	<keyword>Robotic Surgical Procedures</keyword>
	<keyword>Hysterectomy</keyword>
	<keyword>Anesthetics , Local</keyword>
	<keyword>Bupivacaine</keyword>
	<keyword>Pain , Postoperative</keyword>
</DOC>